文献速递肿瘤 PET/CT

使用三(羟基吡啶酮)双功能螯合剂对蛋白质进行简单温和的一步法镓-68标记:一种靶向前列腺特异性膜抗原的68Ga-THP-scFv

Simple, mild, one-step labelling of proteins with gallium-68 using a tris(hydroxypyridinone) bifunctional chelator: a 68Ga-THP-scFv targeting the prostate-specific membrane antigen.
PubMed 文献 · EJNMMI Res · 2017-10-25

本研究评价了三(羟基吡啶酮)(THP)双功能螯合剂用于镓-68标记靶向前列腺特异性膜抗原(PSMA)的单链抗体的效果。THP-mal-J591c-scFv在室温中性pH下5分钟内标记产率>95%,无需纯化,产物在血清中稳定,在DU145-PSMA异种移植瘤中显示快速特异性摄取,90分钟时摄取为5.4±0.5%ID/g,对照瘤为0.5±0.2%ID/g(n=4)。

要点

  • THP-mal可在室温中性pH下5分钟一步法标记镓-68,产率>95%,无需标记后纯化。
  • 68Ga-THP-mal-J591c-scFv在血清中稳定,对PSMA具有选择性结合,IC50为31.5 nM。
  • 在DU145-PSMA异种移植瘤中90分钟摄取为5.4±0.5%ID/g,对照瘤为0.5±0.2%ID/g(n=4)。

核心结论

  • THP-mal双功能螯合剂使蛋白质能在室温中性pH下用镓-68进行简单、快速、定量的一步法标记,无需标记后纯化。
  • 所得镓-68复合物对PSMA具有高亲和力,并在前列腺癌异种移植模型中显示良好的体内靶向特性。

研究设计与样本

  • 研究制备了J591c-scFv单链抗体片段,通过C端半胱氨酸位点特异性偶联THP-mal,并在DU145细胞系及过表达PSMA的DU145-PSMA变体中进行体外评价,在SCID小鼠异种移植瘤中进行体内评价。

主要发现

  • J591c-scFv在HEK293T细胞中产量为4-6 mg/l培养上清,并能与THP-mal双功能螯合剂有效偶联。
  • 5 μg偶联物与镓-68孵育5分钟,室温下标记产率>95%,无需标记后纯化。
  • 68Ga-THP-mal-J591c-scFv在血清中稳定,选择性结合DU145-PSMA细胞系,未修饰J591c-scFv的IC50为31.5 nM。
  • 系列PET/CT显像显示快速、特异性肿瘤摄取并经肾脏排泄清除。
  • 注射后90分钟DU145-PSMA异种移植瘤摄取为5.4±0.5%ID/g,DU145肿瘤为0.5±0.2%ID/g(n=4)。

关键数值与推荐

  • 标记产率>95%:5 μg偶联物与镓-68在室温孵育5分钟,无需标记后纯化。
  • 未修饰J591c-scFv对PSMA的IC50为31.5 nM。
  • 注射后90分钟肿瘤摄取:DU145-PSMA异种移植瘤5.4±0.5%ID/g vs DU145肿瘤0.5±0.2%ID/g(n=4)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Labelling proteins with gallium-68 using bifunctional chelators is often problematic because of unsuitably harsh labelling conditions such as low pH or high temperature and may entail post-labelling purification. To determine whether tris(hydroxypyridinone) (THP) bifunctional chelators offer a potential solution to this problem, we have evaluated the labelling and biodistribution of a THP conjugate with a new single-chain antibody against the prostate-specific membrane antigen (PSMA), an attractive target for staging prostate cancer (PCa). A single-chain variable fragment (scFv) of J591, a monoclonal antibody that recognises an external epitope of PSMA, was prepared in order to achieve biokinetics matched to the half-life of gallium-68. The scFv, J591c-scFv, was engineered with a C-terminal cysteine. RESULTS: J591c-scFv was produced in HEK293T cells and purified by size-exclusion chromatography. A maleimide THP derivative (THP-mal) was coupled site-specifically to the C-terminal cysteine residue. The THP-mal-J591c-scFv conjugate was labelled with ammonium acetate-buffered gallium-68 from a 68Ge/68Ga generator at room temperature and neutral pH. The labelled conjugate was evaluated in the PCa cell line DU145 and its PSMA-overexpressing variant in vitro and xenografted in SCID mice. J591c-scFv was produced in yields of 4-6 mg/l culture supernatant and efficiently coupled with the THP-mal bifunctional chelator. Labelling yields > 95% were achieved at room temperature following incubation of 5 μg conjugate with gallium-68 for 5 min without post-labelling purification. 68Ga-THP-mal-J591c-scFv was stable in serum and showed selective binding to the DU145-PSMA cell line, allowing an IC50 value of 31.5 nM to be determined for unmodified J591c-scFv. Serial PET/CT imaging showed rapid, specific tumour uptake and clearance via renal elimination. Accumulation in DU145-PSMA xenografts at 90 min post-injection was 5.4 ± 0.5%ID/g compared with 0.5 ± 0.2%ID/g in DU145 tumours (n = 4). CONCLUSIONS: The bifunctional chelator THP-mal enabled simple, rapid, quantitative, one-step room temperature radiolabelling of a protein with gallium-68 at neutral pH without a need for post-labelling purification. The resultant gallium-68 complex shows high affinity for PSMA and favourable in vivo targeting properties in a xenograft model of PCa.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Nawaz S, Mullen GED, Sunassee K, et al. Simple, mild, one-step labelling of proteins with gallium-68 using a tris(hydroxypyridinone) bifunctional chelator: a 68Ga-THP-scFv targeting the prostate-specific membrane antigen. EJNMMI Res. 2017. PMID: 29067565. doi:10.1186/s13550-017-0336-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。